Zimmer Biomet (ZBH) officer granted 10,076 restricted stock units vesting from 2027

Rhea-AI Filing Summary

Noor Jehanzeb reported acquisition or exercise transactions in this Form 4 filing.

ZIMMER BIOMET HOLDINGS, INC. reported that officer Noor Jehanzeb received a grant of 10,076 restricted stock units (RSUs). Each RSU represents a contingent right to receive one share of company common stock. The award vests annually over three years in one-third increments starting on February 20, 2027.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Noor Jehanzeb

(Last) (First) (Middle)

345 E. MAIN STREET

(Street)

WARSAW IN 46580

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
ZIMMER BIOMET HOLDINGS, INC. [ ZBH ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	See remarks below.

3. Date of Earliest Transaction (Month/Day/Year)
02/20/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Units	(1)	02/20/2026		A		10,076		(2)	(2)	Common Stock	10,076	$0	10,076	D

Explanation of Responses:

1. Each RSU represents a contingent right to receive one share of Company common stock.

2. Vests annually over three years in increments of one-third each year, commencing February 20, 2027.

Remarks:

Senior Vice President, Chief Strategy, Innovation & Business Development Officer

	/s/ Matthew R. St. Louis, Attorney-in-Fact for Jehanzeb Noor (power of attorney previously filed)	02/24/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did ZIMMER BIOMET (ZBH) report for Noor Jehanzeb?

ZIMMER BIOMET reported that officer Noor Jehanzeb received a grant of 10,076 restricted stock units. These RSUs are a form of equity compensation and give the holder the right to receive company common shares if vesting conditions are met.

How many restricted stock units were granted to Noor Jehanzeb at ZIMMER BIOMET?

Noor Jehanzeb was granted 10,076 restricted stock units (RSUs). After this grant, the Form 4 shows 10,076 derivative securities owned directly, reflecting this entire award as of the reported transaction date of February 20, 2026.

What does each restricted stock unit granted by ZIMMER BIOMET represent?

Each restricted stock unit granted to Noor Jehanzeb represents a contingent right to receive one share of ZIMMER BIOMET common stock. Actual share delivery depends on the units vesting under the schedule and meeting any applicable service or other conditions.

What is the vesting schedule for Noor Jehanzeb’s RSUs at ZIMMER BIOMET (ZBH)?

The 10,076 RSUs granted to Noor Jehanzeb vest annually over three years. Vesting occurs in one-third increments each year, commencing on February 20, 2027, so the award becomes fully vested after three such annual installments.

Did Noor Jehanzeb pay a purchase price for the ZIMMER BIOMET RSU grant?

The Form 4 lists a transaction price per share of 0.0000 for the RSU grant. This indicates the units were provided as compensation rather than purchased in an open-market or cash transaction by the reporting officer.

Is Noor Jehanzeb’s ownership in ZIMMER BIOMET direct or indirect after this RSU grant?

Following the RSU grant, the Form 4 shows 10,076 derivative securities held with direct ownership. The ownership code is reported as “D,” and there is no footnote indicating indirect holding through a separate entity or trust.